Detalhe da pesquisa
1.
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Clin Infect Dis
; 76(2): 201-209, 2023 01 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36196614
2.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34883053
3.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36729167
4.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34480858
5.
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Lancet
; 398(10301): 675-684, 2021 08 21.
Artigo
Inglês
| MEDLINE | ID: mdl-34384540
6.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33798499
7.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34863358
8.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34370971
9.
Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
Vaccine
; 42(8): 2018-2025, 2024 Mar 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38395723
10.
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
J Infect
; 87(3): 230-241, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37331429
11.
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.
Trials
; 24(1): 465, 2023 Jul 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37480110
12.
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
J Infect
; 86(6): 574-583, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37028454
13.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
J Infect
; 87(1): 18-26, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37085049
14.
Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Lancet Glob Health
; 10(10): e1494-e1504, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36113533
15.
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
JCI Insight
; 7(7)2022 04 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35192543
16.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Lancet Infect Dis
; 22(8): 1131-1141, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35550261
17.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
J Infect
; 84(6): 795-813, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35405168
18.
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Lancet Respir Med
; 10(11): 1049-1060, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35690076
19.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Nat Commun
; 12(1): 5861, 2021 10 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34615860
20.
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Lancet Glob Health
; 9(11): e1561-e1568, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34678198